MedTrace Logo

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

NCT05983874 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-06-11

No results posted yet for this study

Summary

An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, given to a Population of Adults in Good General Health Who have Received 3 doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

Conditions

Interventions

BIOLOGICAL

BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage

100µg Month 0 and Month 3

Sponsors & Collaborators

  • 3M

    collaborator INDUSTRY

  • Access to Advanced Health Institute (AAHI)

    collaborator OTHER

  • Polymun Scientific GmbH

    collaborator INDUSTRY

  • International AIDS Vaccine Initiative

    lead NETWORK

Principal Investigators

  • Godelieve de Bree · Amsterdam UMC, location VUmc

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
51 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-16
Primary Completion
2025-03-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05983874 on ClinicalTrials.gov